心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：血浆二甲基精氨酸水平与房颤患者预后相关

2018-08-08 MedSci MedSci原创

心血管房颤预后二甲基精氨酸
关注

一氧化氮（NO）理论上可以增加房颤患者血栓栓塞和出血的发生风险。本研究的目的旨在评估血浆甲基化精氨酸衍生物不对称和对称二甲基精氨酸（ADMA/SDMA）同时也是NO抑制剂与房颤患者预后的相关性。本研究纳入了ARISTOTLE临床试验中的5004名房颤患者，并取得了血浆样本，通过高效液相色谱法对其ADMA/SDMA水平进行了检测，平均随访时间是1.9年。分析结果显示，ADMA/SDMA水平随着患者年

一氧化氮（NO）理论上可以增加房颤患者血栓栓塞和出血的发生风险。本研究的目的旨在评估血浆甲基化精氨酸衍生物不对称和对称二甲基精氨酸（ADMA/SDMA）同时也是NO抑制剂与房颤患者预后的相关性。

本研究纳入了ARISTOTLE临床试验中的5004名房颤患者，并取得了血浆样本，通过高效液相色谱法对其ADMA/SDMA水平进行了检测，平均随访时间是1.9年。分析结果显示，ADMA/SDMA水平随着患者年龄的增加而升高，并且在女性、肾功能损伤、永久性房颤和充血性心衰患者中更高。ADMA/SDMA水平升高的患者CHA2DS2-VASc和HAS-BLED评分更高（p < 0.001），但在糖尿病患者中降低。经多元调整分析后发现，ADMA水平与卒中或全身性栓塞的发生风险（p = 0.034）、死亡（p < 0.0001）相关，而SDMA水平与主要出血事件和死亡（p < 0.001）相关。将ADMA/SDMA加入到CHA2DS2-VASc或HAS-BLED评分可以提高预测房颤患者预后的能力。

本研究结果显示，在口服抗凝治疗的房颤患者中，ADMA水平与血栓发生风险呈弱相关，SDMA与出血和死亡风险呈强相关。

原始出处：

本文系梅斯医学(MedSci)原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-11-20 bnurmamat

    #患者预后#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-09-18 hbwxf

    #JACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2019-06-12 gostraight

    #精氨酸#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-17 canlab

    #二甲基精氨酸#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 12498568m50暂无昵称

    #ACC#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1691994, encodeId=06af1691994b2, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Nov 20 11:08:00 CST 2018, time=2018-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854122, encodeId=ff9f18541228e, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Sep 18 15:08:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928753, encodeId=cee61928e532b, content=<a href='/topic/show?id=3ee5e6449ff' target=_blank style='color:#2F92EE;'>#精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76449, encryptionId=3ee5e6449ff, topicName=精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Wed Jun 12 13:08:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797892, encodeId=23371e978924b, content=<a href='/topic/show?id=6d1f2399263' target=_blank style='color:#2F92EE;'>#二甲基精氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23992, encryptionId=6d1f2399263, topicName=二甲基精氨酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Aug 17 23:08:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325928, encodeId=0470132592822, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614465, encodeId=0385161446557, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Aug 10 07:08:00 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 hittouch

    #房颤患者#

    0

相关资讯

JACC：冠脉微血管功能不良可作为肥胖患者的心血管风险分层因子

除了体重指数（BMI）外，尚需要其他的因素来鉴别肥胖患者的心血管风险。本研究的目的旨在评估肥胖、冠脉微血管功能不良（CMD）和不良反应事件的相关性。本研究对827名心脏灌注正电子发射断层显像显示正常灌注的肥胖患者进行平均5.6年时间的随访，观察事件主要包括死亡、心梗或心衰住院。分析结果显示，BMI与冠脉血流储备（CFR）呈倒J型曲线相关，即在肥胖患者中，CFR随着BMI的升高而降低（p <

Int J Cardiol：成年先天性心脏病患者心血管危险因素

由此可见，对ACHD患者进行获得性心血管疾病的一级和二级预防并未得到充分开展。这突出了教育初级医师以及专科医师对ACHD患者进行获得性心血管疾病一级和二级预防需求的重要性。

盘点：JACC8月第1期研究一览

1. 心衰患者左室射血分数的远期变化动态曲线DOI: 10.1016/j.jacc.2018.05.042http://www.onlinejacc.org/content/72/6/591心衰病人远期的左室射血分数（LVEF）变化曲线尚不清楚。本研究的目的旨在评估心衰伴左室射血分数降低（＜40%）和中等范围LVEF（40%-49%）患者的LVEF随访15年的变化曲线。本研究纳入了1160例心

JAHA：房颤患者的心肌灌注水平和心功能下降

房颤（AF）与心梗的发生相关，AF患者即使没有梗阻性冠心病也会表现出心肌缺血的症状。本研究猜测冠脉微循环功能障碍是导致这种现象的原因。本研究纳入了49例房颤患者（25例阵发性，24例永久性），并对其心肌血流（MBF）及左房左室功能进行了评估，评估的时间点为基线水平、房颤消融术后6个月和9个月，并与匹配的25例窦性心律正常对照进行比较分析。消融术前，房颤患者的左房功能、左室射血分数和应变指数均较低（

CHC2018丨糖尿病患者心血管疾病的预防与管理展望

心血管疾病是糖尿病的重要慢性并发症，是导致糖尿病患者死亡的重要原因，糖尿病患者心血管疾病的预防与管理意义重大。2018年8月3日，CHC年会全体大会上，美国疾病预防与控制中心Edward W.Gregg教授就此问题发表专题讲座。

JACC：胸主动脉瘤的遗传基因筛选

胸主动脉瘤是呈进展性的，且有发生主动脉夹层的风险。有高达25%的胸主动脉瘤患者拥有可遗传的基因变异。本研究的目的旨在通过临床基因组资源（ClinGen）来精确地识别导致遗传性胸主动脉瘤和夹层（HTAAD）的基因。本研究通过半定量的ClinGen框架来评估53个候选基因与HTAAD的相关性。如果一个基因与孤立性胸主动脉瘤相关，并且能引起主动脉的治疗和家系的筛选，那么该基因被归为HTAAD致病基因。根